Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) EBT Margin (2016 - 2025)

United Therapeutics' EBT Margin history spans 17 years, with the latest figure at 56.19% for Q4 2025.

  • For Q4 2025, EBT Margin rose 507518.0% year-over-year to 56.19%; the TTM value through Dec 2025 reached 53.85%, down 1828.0%, while the annual FY2025 figure was 53.85%, 36.0% up from the prior year.
  • EBT Margin for Q4 2025 was 56.19% at United Therapeutics, up from 54.78% in the prior quarter.
  • Across five years, EBT Margin topped out at 29540.0% in Q4 2023 and bottomed at 5018.99% in Q4 2024.
  • The 5-year median for EBT Margin is 52.6% (2024), against an average of 1270.06%.
  • The largest annual shift saw EBT Margin surged 2950362bps in 2023 before it crashed -3455899bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 33.84% in 2021, then rose by 8bps to 36.38% in 2022, then soared by 81102bps to 29540.0% in 2023, then plummeted by -117bps to 5018.99% in 2024, then surged by 101bps to 56.19% in 2025.
  • Per Business Quant, the three most recent readings for UTHR's EBT Margin are 56.19% (Q4 2025), 54.78% (Q3 2025), and 51.14% (Q2 2025).